<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03335280</url>
  </required_header>
  <id_info>
    <org_study_id>181016</org_study_id>
    <secondary_id>NCI-2020-00335</secondary_id>
    <nct_id>NCT03335280</nct_id>
  </id_info>
  <brief_title>68Ga-citrate PET/MR Imaging for Glioma</brief_title>
  <official_title>68Ga-citrate PET/MR Imaging for the Evaluation of Glioma in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Susan Chang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Brain Tumor Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single center, open-label study in adult patients with presumed World
      Health Organization (WHO) grade 3 or 4 glioma who will be undergoing surgical resection as
      standard of care. In some cases, patients will have had biopsy. Study participants will
      undergo 68Ga-citrate Positron Emission Tomography / magnetic resonance (PET/MR) prior to
      surgery.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low Accrual
  </why_stopped>
  <start_date type="Actual">February 26, 2019</start_date>
  <completion_date type="Actual">April 24, 2020</completion_date>
  <primary_completion_date type="Actual">April 24, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum standardized uptake value (SUVmax)</measure>
    <time_frame>1 day</time_frame>
    <description>The location and extent of 68Ga-citrate uptake will be compared to both same day magnetic resonance imaging (MRI) and subsequent pathology. SUVmax will be the outcome of interest and summarized with descriptive measures. SUVmax will be compared via a two-sided two-sample equal-variance t-test between those patients positive for PTEN deletion and those negative for PTEN deletion.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">2</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>Positive for PTEN deletion</arm_group_label>
    <description>Confirmed by immunohistochemistry of tissue biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative for PTEN deletion</arm_group_label>
    <description>Confirmed by immunohistochemistry of tissue biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-citrate PET/MR</intervention_name>
    <description>Study participants will undergo the 68Ga-citrate PET/MR imaging after all screening and baseline assessments have been completed. Patient shall begin imaging between 120 and 360 minutes after the injection of the radiopharmaceutical. Coverage for the scan will extend from the patient's vertex to the neck. The entire imaging study will take roughly 90 minutes.</description>
    <arm_group_label>Negative for PTEN deletion</arm_group_label>
    <arm_group_label>Positive for PTEN deletion</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with WHO grade 3 or 4 glioma planning to undergo surgery with availability of
        immunohistochemistry of tissue
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  World Health Organization (WHO) grade 3 or 4 glioma planning to undergo surgery

          -  Age &gt;= 18 yrs.

          -  Karnofsky performance status of &gt;= 60

          -  Ability to understand a written informed consent document, and the willingness to sign
             it.

        Cohort A:

        - Positive for Phosphatase and Tensin Homolog (PTEN) deletion, confirmed by
        immunohistochemistry of tissue biopsy

        Cohort B:

        - Negative for PTEN deletion, confirmed by immunohistochemistry of tissue biopsy

        Exclusion Criteria:

          -  Contraindications to Positron Emission Tomography (PET) imaging (e.g. pregnant or
             breast-feeding woman)

          -  Contraindications to magnetic resonance (MR) imaging (e.g. pacemakers, metallic
             implants, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 18, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Susan Chang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT03335280/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

